Upon completion of successful human trials and regulatory approval, the joint venture's goal is to start delivering the second-generation vaccine in 2022 as soon as is practically possible
Focused medicines company delivering strong operational performance. Building depth in five core therapeutic areas, strength in technology platforms, and a balanced geographic footprint
The product is synthetically developed as compared to the current process of drawing the same from blood plasma and is backed by a granted global patent
Subscribe To Our Newsletter & Stay Updated
